- Home
- News
- Social Media Activities
- OSAWELL Signs Memorandum of Agreement (MoA) with the University of Malaya Joining Forces to Advance Clinical Research on Digital Oral Appliances and Accelerate Expansion in the Asia-Pacific Market
OSAWELL Signs Memorandum of Agreement (MoA) with the University of Malaya Joining Forces to Advance Clinical Research on Digital Oral Appliances and Accelerate Expansion in the Asia-Pacific Market
Kuala Lumpur, Malaysia, April 25, 2025 — Taiwanese innovator in dental and sleep medicine, OSAWELL, officially signed a Memorandum of Agreement (MoA) today with the University of Malaya (UM) to launch a collaborative clinical research project focused on digital oral appliance therapy (OAT) for obstructive sleep apnea (OSA).
Founded in 1905, the University of Malaya (UM) is Malaysia’s oldest and top-ranked comprehensive university, renowned for its world-class medical and dental education and research. As a prestigious national university and one of Asia’s leading institutions, UM will combine its robust clinical resources in medicine, dentistry, and sleep medicine with OSAWELL’s advanced digital technologies and manufacturing capabilities. Together, they will validate the clinical efficacy of OAT solutions across diverse patient populations, driving the clinical adoption of innovative treatment approaches.
"Our collaboration with the University of Malaya marks a critical milestone in OSAWELL’s Asia-Pacific strategic expansion," said Jerry Cheng, CEO of ShareSmile. "As demand for OSA treatment continues to rise across the region, we are leveraging Taiwan as our R&D hub, expanding international medical education partnerships, and progressively building a localized digital sleep medicine network across Asia."
OSAWELL has secured multiple technology patents in Taiwan and the United States, and continues to invest in AI-driven design, customized manufacturing, and digital twin technologies, aiming to deliver personalized OAT solutions tailored to the anatomical characteristics of Asian populations.
The first phase of clinical trials is set to commence in the second half of 2025, focusing on enhancing patient compliance, optimizing airway patency outcomes, and simultaneously launching educational and academic exchange initiatives.